PTC Therapeutics (PTCT) recently issued full year 2026 product revenue guidance of US$700 million to US$800 million, excluding Evrysdi royalties and collaboration revenue. This guidance serves as a key reference point for investors tracking the stock.

The 12.18% 3 month share price return and 62.0% 1 year total shareholder return suggest momentum has been building around PTC Therapeutics, with the new 2026 product revenue guidance adding to recent interest at a share price of US$75.25.

If this kind of guidance driven story has your attention, it could be a good moment to broaden your search across healthcare stocks for other opportunities in the sector.

With the stock at US$75.25, a 62.0% 1 year total return and an analyst price target of US$83.57, the key question is whether PTCT still trades at a discount or if markets are already pricing in future growth.

Most Popular Narrative: 8.1% Undervalued

Against the last close of $75.25, the most followed narrative points to a fair value of about $81.86, framing PTC Therapeutics as modestly undervalued based on its modeled cash flows and risk profile.

Robust late-stage pipeline progress, including 2 NDAs under FDA review (vatiquinone for Friedreich's ataxia and Translarna), and upcoming potential Phase 3 entry for PTC518 in Huntington's (partnered with Novartis), increases the probability of further product launches, expanding addressable markets, and diversifying near

and medium-term revenue streams. This may improve overall revenue stability and future earnings visibility.

Want to see what sits behind that valuation gap? The narrative focuses on changing revenue mix, shifting margins and a future earnings profile that is expected to differ from today. Curious which specific long term assumptions support that $81.86 figure and how the 7.77% discount rate shapes the outcome?

Result: Fair Value of $81.86 (UNDERVALUED)

However, the story could change quickly if Sephience uptake slows, or if regulatory and pricing pressures hit key rare disease products harder than analysts currently model.

Build Your Own PTC Therapeutics Narrative

If you look at the numbers and come to a different conclusion, or simply prefer to test your own assumptions, you can build a complete narrative in just a few minutes using Do it your way.

A great starting point for your PTC Therapeutics research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about sharpening your stock list, do not stop at one company. Use targeted screeners to surface other ideas that fit your style.

• Hunt for potential high upside plays with these 3523 penny stocks with strong financials that pair smaller market caps with stronger fundamentals than you might expect.
• Position yourself in the AI trend by scanning these 23 AI penny stocks that tie artificial intelligence themes to listed businesses.
• Focus on price versus fundamentals with these 871 undervalued stocks based on cash flows that highlight companies trading below estimated cash flow based value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.